MarketPeel
Insider Trading Intelligence
Pricing
…
NS

Natarajan Sethuraman

TRDA
PRESIDENT, RESEARCH & DEVELOP. · ENTRADA THERAPEUTICS, INC. · CIK 0001873394
FILING MIX · LIFETIME34%/66%
BUYS
17
SELLS
33
TOTAL VALUE
$1.87M
COMPANIES
1
ACTIVE SINCE
Oct 2021
HOLDINGS NOW
216,317
AVG SELL PX
$16.00
TRADE KIND
SHOWING 50 / 50
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
19 backtested trades · 8 horizons · 18 pending
Forward-return performance of every backtestable P/S trade by Natarajan Sethuraman, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d19+42.11%-2.94%+0.73%-3.67%+0.97%—
14d19+78.95%-7.43%+0.63%-8.06%-4.07%—
30d19+47.37%-4.45%+1.47%-3.10%-1.63%—
60d19+63.16%-8.36%+2.73%-11.09%-4.66%—
90d19(1 pending)+72.22%-14.03%+3.49%-17.52%-29.49%—
180d19(1 pending)+83.33%-32.18%+2.21%-34.39%-47.24%—
1y19(1 pending)+100.00%-55.94%+15.51%-71.45%-75.15%—
2y19(15 pending)+100.00%-56.62%+39.12%-95.74%-97.98%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
TRDA · 216,317 shares · as of May 4, 2026
063,425126,850190,274253,69920222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 17 buys / 33 sellsCOVERAGE · 19 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
25,907$15.39$398.8K216,317May 4, 2026May 4, 2026 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
President, Research & Develop.
7,577$11.76$89.1K242,224Mar 3, 2026Mar 3, 2026 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
President, Research & Develop.
3,898$11.66$45.4K249,801Mar 2, 2026Mar 3, 2026 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
55,800——253,699Mar 1, 2026Mar 3, 2026 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
83,200——83,200Mar 1, 2026Mar 3, 2026 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
President, Research & Develop.
1,760$5.43$9.6K197,899Sep 2, 2025Sep 4, 2025 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
President, Research & Develop.
6,138$11.68$71.7K199,659Mar 3, 2025Mar 4, 2025 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
90,800——90,800Mar 1, 2025Mar 4, 2025 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
60,800——205,797Mar 1, 2025Mar 4, 2025 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
11,703$20.15$235.8K144,997Dec 3, 2024Dec 3, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
4,088$20.26$82.8K156,700Dec 2, 2024Dec 3, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
100$20.00$2.0K160,788Nov 29, 2024Dec 3, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,700$20.04$54.1K160,888Nov 13, 2024Nov 13, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,409$20.01$28.2K163,588Nov 11, 2024Nov 13, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,745$19.32$53.0K164,997Nov 6, 2024Nov 6, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
9,554$18.71$178.8K167,742Nov 6, 2024Nov 6, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,171$18.18$94.0K177,296Nov 5, 2024Nov 6, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
749$18.02$13.5K182,467Nov 4, 2024Nov 6, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
600$18.00$10.8K183,216Oct 16, 2024Oct 18, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,642$15.09$39.9K183,816Sep 9, 2024Sep 10, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
600$15.24$9.1K186,458Sep 6, 2024Sep 10, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Scientific Officer
167$15.13$2.5K187,058Sep 5, 2024Sep 5, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Scientific Officer
955$15.42$14.7K187,225Sep 4, 2024Sep 5, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Scientific Officer
14$17.70$248188,180Sep 3, 2024Sep 5, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Scientific Officer
151$16.93$2.6K188,194Sep 3, 2024Sep 5, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Scientific Officer
469$15.76$7.4K188,345Sep 3, 2024Sep 5, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
638$18.00$11.5K188,814Jul 15, 2024Jul 16, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
600$18.00$10.8K189,452Jul 12, 2024Jul 16, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
9,675$15.19$146.9K190,052May 20, 2024May 20, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
8,305$15.14$125.8K199,727May 17, 2024May 20, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,000$15.00$15.0K208,032May 16, 2024May 20, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Scientific Officer
1,505$12.28$18.5K209,032Mar 5, 2024Mar 5, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Scientific Officer
347$12.42$4.3K210,951Mar 4, 2024Mar 5, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Scientific Officer
414$13.37$5.5K210,537Mar 4, 2024Mar 5, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
66,800——66,800Mar 1, 2024Mar 5, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
44,100——211,298Mar 1, 2024Mar 5, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Scientific Officer
449$14.46$6.5K167,198Sep 5, 2023Sep 6, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
21,500——21,500Sep 1, 2023Sep 6, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
14,200——167,647Sep 1, 2023Sep 6, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,961$18.00$71.3K171,325Apr 17, 2023Apr 19, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Scientific Officer
1,058$11.60$12.3K189,486Mar 2, 2023Mar 3, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
43,000——43,000Mar 1, 2023Mar 3, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
28,400——190,544Mar 1, 2023Mar 3, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
21,500——21,500Mar 1, 2023Apr 19, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
14,200——175,286Mar 1, 2023Apr 19, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,794——162,144Sep 1, 2022Sep 6, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
34,763——34,763Jul 1, 2022Jul 6, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
11,588——156,350Mar 1, 2022Mar 3, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
69,525——69,525Mar 1, 2022Mar 3, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
243,639——243,639Oct 28, 2021Nov 1, 2021 ↗View →
Other insiders · TRDA
Loading peer insiders…
About this filer
CIK 0001873394
ROLE
President, Research & Develop.
PRIMARY
TRDA
COMPANIES
1
ACTIVE SINCE
Oct 2021
MARKETPEEL · /INSIDER/0001873394DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback